Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sandoz Group Ltd ( (CH:SDZ) ) just unveiled an update.
Sandoz has announced a potential acquisition of Just-Evotec Biologics’ activities in Toulouse, France, aiming to enhance its biosimilar development and manufacturing capabilities. This move aligns with Sandoz’s strategic goal to capitalize on the projected USD 300 billion biosimilar market over the next decade, offering strategic flexibility and reinforcing its in-house capabilities. The acquisition would complement Sandoz’s existing investments in biosimilar manufacturing and development, with the Toulouse site playing a crucial role in scaling operations efficiently and cost-effectively.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF50.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz is a global leader in generic and biosimilar medicines, headquartered in Basel, Switzerland. With a history dating back to 1886, Sandoz offers a diverse portfolio of approximately 1,300 products addressing a wide range of diseases. The company is committed to pioneering access for patients and has a significant impact on global healthcare savings.
Average Trading Volume: 969,702
Technical Sentiment Signal: Buy
Current Market Cap: CHF20.93B
For detailed information about SDZ stock, go to TipRanks’ Stock Analysis page.